IGC Pharma (NYSE: IGC) inks 12-part New to The Street deal
Rhea-AI Filing Summary
IGC Pharma, Inc. entered into a strategic 12-part national media partnership with FMW Media Works’ New to The Street platform to support its investor relations and corporate communications. The campaign will use long-form TV interviews, commercials, digital channels, and outdoor placements in major U.S. financial markets.
IGC will appear on sponsored programming on Fox Business and Bloomberg Television, with additional reach through more than 4.45 million YouTube subscribers, Times Square and New York City Financial District billboards, and curated events aimed at accredited investors. The company frames this effort as enhancing investor awareness while it advances its clinical-stage Alzheimer’s and metabolic disorder pipeline.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
strategic national media partnership financial
accredited investors financial
Phase 2 trial technical
forward-looking statements regulatory
investor relations financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On March 30, 2026, IGC Pharma, Inc. (the “Company”) issued a press release announcing a strategic national media partnership with FMW Media Works LLC (New to The Street), a financial media platform, as part of the Company’s investor relations and corporate communications initiatives.
The information contained in this Item 8.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit No. | Description | |
| 99.1 | Press Release dated March 30, 2026 | |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL). |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IGC PHARMA, INC. | ||
| Dated: March 30, 2026 | By: | /s/ Ram Mukunda |
| Name: | Ram Mukunda | |
| Title: | Chief Executive Officer and President | |
2
Exhibit 99.1
IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness
POTOMAC, MARYLAND - March 30, 2026 - IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced a strategic 12-part national media partnership with New to The Street, a leading financial media platform known for its integrated investor engagement and national television distribution.
The collaboration is designed to enhance IGC Pharma’s visibility across both institutional and retail investor audiences through a coordinated, multi-channel media strategy. The campaign will include long-form televised interviews, national television commercial distribution, digital amplification, and high-visibility outdoor placements in key financial markets.
As part of the initiative, IGC Pharma will be featured on New to The Street’s sponsored programming on Fox Business and Bloomberg Television. The campaign will also be amplified through digital channels reaching a combined audience of more than 4.45 million YouTube subscribers, as well as through outdoor billboard placements in Times Square and the New York City Financial District and earned media distribution across major U.S. broadcast affiliates.
New to The Street’s platform integrates national television exposure with digital, social, and outdoor media distribution, as well as curated events designed to facilitate engagement with accredited investors. The Company believes that participation in such platforms supports broader market awareness while maintaining a focus on disciplined clinical execution and scientific development.
About New to The Street
New to The Street is a U.S. and international sponsored television platform broadcasting weekly programming on Fox Business and Bloomberg Television. The platform features long-form interviews with public and private companies and combines national television exposure with digital distribution, social media engagement, outdoor advertising, and access to accredited investors through curated events.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. Our lead asset, IGC-AD1, is a therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With a complete patent portfolio and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission (“SEC”) filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 27, 2025, and on Forms 10-Q filed with the SEC on August 14, 2025, and on November 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. IGC Pharma, Inc. assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Contact Information:
Walter Frank / John Nesbett
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200